Table 2.

TAA-induced cytokine and proliferative response of PBMC from patients with PDA before and after CT treatment

	ENO1						FUBP1						K2C8						G3P
	Before CT		After CT round				Before CT		After CT round				Before CT		After CT round				Before CT		After CT round
			I		II				I		II				I		II				I		II
Patient	IFN-γ/IL-10	SI	IFN-γ/IL-10	SI	IFN-γ/IL-10	SI	IFN-γ/IL-10	SI	IFN-γ/IL-10	SI	IFN-γ/IL-10	SI	IFN-γ/IL-10	SI	IFN-γ/IL-10	SI	IFN-γ/IL-10	SI	IFN-γ/IL-10	SI	IFN-γ/IL-10	SI	IFN-γ/IL-10	SI
3	0.3	0.8	null	1	17.9	1.7	3.1	1.1	17.4	0.7	null	0.6	7.5	0.7	25	0.4	null	0.2	3.2	0.8	38.2	4.1	17.9	0.9
5	null	1.3	null	1.9	null	0.8	0.5	1.2	9.6	2.9	12.9	4.7	0	1.5	0	1.4	null	2.5	0.1	1.6	0	3	0	3.1
9	null	1.1	null	1.3	89.3	1.9	0	0.9	33.9	4.5	5.8	1.4	0	0.9	23.4	3.4	7.9	1.2	0	1.3	466.3	4.4	6.9	2.8
10	null	1.2	null	1.1	16.9	1.2	0.3	1.1	0.4	2.6	25.7	3.5	0.3	1	0.9	3.5	7.4	2.7	null	2	181.3	8	null	2.4
19	null	1.3	null	1	null	0.7	3.4	1.2	17.5	0.9	null	0.8	3.2	1	12.2	0.7	null	1	0	1	75.4	0.8	null	0.6
24	132.7	1.3	0.4	1.2	46.5	0.3	0.3	0.6	2.1	0.4	110.5	0.3	0.2	0.6	0.4	4.6	103.6	6	2.8	0.4	10.8	3.8	163.4	0.3
25	null	1.5	null	1.1	null	2.1	0.4	2.3	0	2.3	1.7	5.2	1.9	2.5	0.5	2.6	0.9	4.4	null	1.9	null	1.6	null	2.7
27	null	1.2	null	1.3	null	1	null	1.4	1.2	2.6	2.2	2.1	null	1	0.7	1.9	0.3	1.4	null	1.2	0	1.5	0	1.5
30	null	1.9	130.3	1.4	null	1.7	0	1.6	4.2	3	5.1	3.9	0.6	1.3	0.7	1.6	0.9	2.6	0	1.2	0	3.2	0	2.6
32	null	1	null	2.1	2.6	13.7	null	1	0.1	0.8	0.7	1.5	null	1	0.1	1.3	0	0.6	null	1	null	0.8	0.1	1.3
41	null	1.6	null	1.3	null	1.3	1.8	5.8	3.7	5.6	0	1.6	3.8	6.8	0.6	4.3	0.3	2.4	0.3	11	0.4	7.4	0.3	5.4
84	0.1	1.2	0.04	2.4	null	1.5	0.2	2.3	0.08	1.9	1.9	2.9	2	2.3	0.25	1.8	0	3	0.3	2.8	0	1.1	0	5.4
87	null	1.9	null	1.6	32	2.8	13.4	2.3	null	1.6	null	3.8	82.9	2.8	40.6	3.2	125.5	4.9	180.3	13.3	null	7.4	76	9

CT, chemotherapy; PBMC, peripheral blood mononuclear cells; PDA, pancreatic ductal adenocarcinoma; SI, stimulation index; TAA, tumor-associated antigens.